MYSTIC: Developing biomarkers for metastatic NSCLC
MYSTIC: Developing biomarkers for metastatic NSCLC
Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma
Latest updates in melanoma research
Gynaecological cancer: Where are we now?
Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma
CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
ASCO GU 2019 renal highlights
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer